Corcept Therapeutics

YTD

ALL

Trade Corcept Therapeutics 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About CORT

Corcept Therapeutics, Inc. engages in the business of discovering and developing pharmaceutical products and medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol. The company was founded by David B.

CEO

Joseph K. Belanoff

CEOJoseph K. Belanoff

Employees

730

Employees730

Headquarters

Redwood City, California

HeadquartersRedwood City, California

Founded

1998

Founded1998

Employees

730

Employees730

CORT Key Statistics

Market cap

13.04B

Market cap13.04B

Price-Earnings ratio

272.46

Price-Earnings ratio272.46

Dividend yield

—

Dividend yield—

Average volume

1.24M

Average volume1.24M

High today

$122.21

High today$122.21

Low today

$104.94

Low today$104.94

Open price

$112.00

Open price$112.00

Volume

4.50M

Volume4.50M

52 Week high

$122.21

52 Week high$122.21

52 Week low

$28.66

52 Week low$28.66

Stock Snapshot

The current Corcept Therapeutics(CORT) stock price is $118.40, with a market capitalization of 13.04B. The stock trades at a price-to-earnings (P/E) ratio of 272.46.

During the trading session on 2026-07-30, Corcept Therapeutics(CORT) shares reached a daily high of $122.21 and a low of $104.94. At a current price of $118.40, the stock is +12.8% higher than the low and still -3.1% under the high.

Trading activity shows a volume of 4.5M, compared to an average daily volume of 1.24M.

Over the past 52 weeks, Corcept Therapeutics(CORT) stock has traded between a high of $122.21 and a low of $28.66.

CORT News

Investing.com 9h

Corcept Therapeutics stock hits 52-week high at 112.0 USD - Investing.com

...

TipRanks 12h

Corcept Therapeutics price target raised to $165 from $88 at Piper Sandler

Piper Sandler raised the firm’s price target on Corcept Therapeutics (CORT) to $165 from $88 and keeps an Overweight rating on the shares. The firm notes Corcep...

Benzinga 16h

Corcept Therapeutics Stock Soars 22% After Hours: Here's What You Need To Know

Revenue and EPS Sail Past Analyst Targets The California-based biopharmaceutical company reported second-quarter revenue of $256.1 million for the period ended...

Analyst ratings

83%

of 6 ratings

Buy

83.3%

Hold

Sell

16.7%

More CORT News

Simply Wall St 5d

Corcept Therapeutics Could Be 8% Pricey After Lifyorli Approval And Estimate Upgrades

Corcept Therapeutics (CORT) is back in focus after the FDA approved Lifyorli, its relacorilant combination for platinum resistant ovarian cancer. This developme...

Simply Wall St 6d

Corcept Therapeutics Is Up 6.8% After Upbeat Q2 Preview And Analyst Upgrades - Has The Bull Case Changed?

Corcept Therapeutics announced in July that it would report its second-quarter 2026 results and host a corporate update call, while analysts recently lifted the...

People also own

Based on the portfolios of people who own CORT. This list is generated using Robinhood data, and it’s not a recommendation.

Novo Nordisk

Broadcom

Robinhood Markets

Palantir Technologies

Palo Alto Networks

Taiwan Semiconductor Manu…

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.